1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 5,400 | 5,600 | 13:04 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| BIOCYTOGEN PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| Do | BIOCYTOGEN-B (02315): ARTICLES OF ASSOCIATION | - | HKEx | ||
| Do | BIOCYTOGEN-B (02315): POLL RESULTS OF THE 2025 ANNUAL GENERAL MEETING HELD ON MAY 21, 2026 | - | HKEx | ||
| 07.05. | BIOCYTOGEN-B (02315): CLARIFICATION ANNOUNCEMENT | - | HKEx | ||
| 27.04. | BIOCYTOGEN-B (02315): FIRST QUARTERLY REPORT FOR THE THREE MONTHS ENDED MARCH 31, 2026 | 3 | HKEx | ||
| 23.04. | BIOCYTOGEN-B (02315): FORM OF PROXY OF H SHAREHOLDERS FOR THE USE AT THE 2025 ANNUAL GENERAL MEETING HELD ON THURSDAY, MAY 21, 2026 | - | HKEx | ||
| 23.04. | BIOCYTOGEN-B (02315): NOTICE OF THE 2025 ANNUAL GENERAL MEETING | - | HKEx | ||
| 23.04. | BIOCYTOGEN-B (02315): CIRCULAR FOR THE 2025 ANNUAL GENERAL MEETING | 1 | HKEx | ||
| 21.04. | BIOCYTOGEN-B (02315): 2025 ENVIRONMENTAL, SOCIAL AND GOVERNANCE (ESG) REPORT | 1 | HKEx | ||
| 21.04. | BIOCYTOGEN-B (02315): 2025 ANNUAL REPORT | 1 | HKEx | ||
| 15.04. | BIOCYTOGEN-B (02315): DATE OF BOARD MEETING | 1 | HKEx | ||
| 02.04. | Biocytogen and Sihuan partner to advance new therapeutics for weight loss | 2 | Pharmaceutical Technology | ||
| 01.04. | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen und Sihuan Pharmaceutical kündigen strategische Partnerschaft auf dem Gebiet der Gewichtsreduktion und darüber hinaus an | 331 | Business Wire | Biocytogen Pharmaceuticals (Peking) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), ein weltweit tätiges Biotechnologieunternehmen, das die Forschung und Entwicklung neuartiger, Antikörper-basierter... ► Artikel lesen | |
| 01.04. | BIOCYTOGEN-B (02315): VOLUNTARY ANNOUNCEMENT BIOCYTOGEN AND SIHUAN PHARMACEUTICAL ANNOUNCE STRATEGIC PARTNERSHIP TO ADVANCE INNOVATIVE DRUG DEVELOPMENT ... | 1 | HKEx | ||
| 30.03. | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen erteilt Taisho Pharmaceutical eine Lizenz für seine RenNano-Plattform zur Entwicklung von vollständig humanen, ausschließlich aus schweren Ketten bestehenden Antikörpern | 304 | Business Wire | Biocytogen Pharmaceuticals (Peking) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), ein weltweit tätiges Biotechnologieunternehmen, das die Forschung und Entwicklung neuartiger, auf Antikörpern... ► Artikel lesen | |
| 27.03. | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen gibt die Erteilung der IND-Genehmigung durch die FDA für NEOK002 seines Partners NEOK Bio bekannt, das auf solide Tumore abzielt | 1.291 | Business Wire | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), ein globales Biotechnologieunternehmen, das die Forschung und Entwicklung neuartiger antikörperbasierter Medikamente... ► Artikel lesen | |
| 27.03. | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen Announces FDA IND Clearance for Partner NEOK Bio's NEOK002 Targeting Solid Tumors | 510 | Business Wire | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative... ► Artikel lesen | |
| 26.03. | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Full Year Profit Advances | 1 | RTTNews | ||
| 26.03. | BIOCYTOGEN-B (02315): VOLUNTARY ANNOUNCEMENT BIOCYTOGEN ANNOUNCES FDA IND CLEARANCE FOR PARTNER NEOK BIO'S NEOK002, ENTERING INTO AN IMPORTANT MILESTONE ... | - | HKEx | ||
| 26.03. | BIOCYTOGEN-B (02315): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025 | 1 | HKEx | ||
| 26.03. | BIOCYTOGEN-B (02315): PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION | - | HKEx |
1 2 3 4 Weiter >>
65 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 0,037 | +18,59 % | MEDIGENE AG im Fokus - ruhige Einordnung der Schwäche | ||
| BIOFRONTERA | 2,390 | -1,65 % | Biofrontera stock rating cut to Speculative Buy by Benchmark | ||
| CLINUVEL | 5,482 | -0,07 % | Clinuvel Pharmaceuticals Limited: CLINUVEL receives final EMA scientific advice for pivotal Phase III vitiligo study | EXECUTIVE SUMMARY final European scientific advice received for pivotal Phase III vitiligo studyEMA emphasised its "totality of evidence" approachcentral photographic review and validated disease... ► Artikel lesen | |
| EDITAS MEDICINE | 2,310 | -2,94 % | Editas Medicine, Inc.: Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting | CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical... ► Artikel lesen | |
| ASEP MEDICAL | 0,100 | 0,00 % | CSE Bulletin: Suspensions - VSBLTY Groupe Technologies Corp., NuRAN Wireless Inc., GOAT Industries Ltd., BYT Holdings Ltd., ASEP Medical Holdings Inc., BioVaxys Technology Corp. | Le 6 mai/May 2026
Effective immediately, the following companies are suspended pursuant to CSE Policy 3. The suspensions are considered Regulatory Halts as defined in National Instrument 23-101 Trading... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 3,200 | 0,00 % | Cellectar Biosciences, Inc. - S-1, General form for registration of securities | ||
| CARDIFF ONCOLOGY | 1,457 | -5,27 % | Cardiff Oncology kündigt Webcast zu neuen Studiendaten für Krebsmedikament an | ||
| CLEAN HARBORS | 246,40 | -0,32 % | Clean Harbors founder McKim to retire from board this summer | ||
| MESOBLAST | 1,258 | -3,23 % | Globaler Biotech-Wettlauf und die Zukunft der Plattformstrategie - Warum Mesoblast auf den Pfaden von großen Konzernen wie Merck KGaA wandert | ||
| LIR LIFE SCIENCES | 0,336 | -5,08 % | Lir Life Sciences Corp.: LIR Life Sciences Announces Initiation of Phase 1 Macromolecule-Enabled Transdermal Delivery Development with Neuland Laboratories | VANCOUVER, BC / ACCESS Newswire / May 22, 2026 / LIR Life Sciences Corp. (CSE:SKNY)(OTCPK:BBCMF)(Frankfurt:N790, WKN:A41QA9) ("LIR" or the "Company")is pleased to announce that Neuland Laboratories... ► Artikel lesen | |
| SPERO THERAPEUTICS | 2,376 | +0,08 % | Spero Therapeutics, Inc.: Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update | Spero announced the resubmission of tebipenem HBr New Drug Application (NDA) to the FDA for complicated urinary tract infections (cUTI), including pyelonephritis in December 2025In February, Spero's... ► Artikel lesen | |
| PROTALIX BIOTHERAPEUTICS | 1,742 | -3,54 % | Protalix BioTherapeutics, Inc. - 8-K, Current Report | ||
| CSTONE PHARMACEUTICALS | 0,863 | -2,53 % | CStone Pharmaceuticals: CStone Announces FDA Clearance of IND Application for Its Novel Trispecific Antibody CS2009 (PD-1/VEGF/CTLA-4) to Advance into Phase II Clinical Trial | CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to initiate... ► Artikel lesen | |
| PALVELLA THERAPEUTICS | 99,00 | 0,00 % | Palvella Therapeutics Inc.: Palvella Therapeutics Named Healthcare & Life Sciences Company of the Year at the Philadelphia Alliance for Capital and Technologies (PACT) Ecosystem Awards | ||
| PURPLE BIOTECH | 2,890 | +0,35 % | Purple Biotech Ltd.: Purple Biotech Announces CEO Transition | Gil Efron to Step Down as CEO in August 2026 for Health Considerations; Will Continue to Lead Corporate Development REHOVOT, Israel, March 13, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (NASDAQ/TASE:... ► Artikel lesen |
BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,010 (+0,18 %) liegt der Kurs bei 5,510 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD finden Sie auf Wallstreet Online.